Woodstock Corp Buys 1,945 Shares of Epizyme, Inc. (EPZM)
Woodstock Corp boosted its position in shares of Epizyme, Inc. (NASDAQ:EPZM) by 5.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 37,078 shares of the biopharmaceutical company’s stock after buying an additional 1,945 shares during the period. Woodstock Corp owned approximately 0.06% of Epizyme worth $560,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Principal Financial Group Inc. raised its position in Epizyme by 0.5% in the first quarter. Principal Financial Group Inc. now owns 94,173 shares of the biopharmaceutical company’s stock valued at $1,615,000 after buying an additional 515 shares during the last quarter. Legal & General Group Plc increased its stake in Epizyme by 8.9% in the first quarter. Legal & General Group Plc now owns 9,684 shares of the biopharmaceutical company’s stock worth $165,000 after buying an additional 795 shares during the last quarter. American International Group Inc. increased its stake in Epizyme by 7.1% in the first quarter. American International Group Inc. now owns 24,779 shares of the biopharmaceutical company’s stock worth $425,000 after buying an additional 1,638 shares during the last quarter. Teachers Advisors LLC increased its stake in Epizyme by 3.1% in the first quarter. Teachers Advisors LLC now owns 69,922 shares of the biopharmaceutical company’s stock worth $1,199,000 after buying an additional 2,093 shares during the last quarter. Finally, Metropolitan Life Insurance Co. NY increased its position in Epizyme by 11.9% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 30,680 shares of the biopharmaceutical company’s stock worth $371,000 after buying an additional 3,269 shares in the last quarter. Institutional investors own 81.30% of the company’s stock.
Epizyme, Inc. (NASDAQ:EPZM) opened at 13.60 on Tuesday. The firm’s market capitalization is $793.67 million. The company’s 50-day moving average price is $13.86 and its 200-day moving average price is $14.31. Epizyme, Inc. has a 12-month low of $7.02 and a 12-month high of $18.50.
Epizyme (NASDAQ:EPZM) last issued its quarterly earnings data on Friday, August 4th. The biopharmaceutical company reported ($0.48) EPS for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.08. The firm had revenue of $10 million during the quarter, compared to analyst estimates of $3.95 million. Epizyme had a negative return on equity of 58.97% and a negative net margin of 1,376.33%. The company’s revenue for the quarter was up 2027.7% on a year-over-year basis. During the same period in the previous year, the company posted ($0.49) EPS. Equities analysts expect that Epizyme, Inc. will post ($2.42) EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This piece was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2017/08/08/epizyme-inc-epzm-shares-bought-by-woodstock-corp-updated-updated-updated.html.
A number of equities analysts have commented on EPZM shares. Oppenheimer Holdings, Inc. set a $26.00 price objective on shares of Epizyme and gave the stock a “buy” rating in a report on Monday, June 5th. Zacks Investment Research raised shares of Epizyme from a “hold” rating to a “buy” rating and set a $18.00 price objective for the company in a report on Tuesday, May 16th. HC Wainwright reiterated a “buy” rating and issued a $25.00 target price on shares of Epizyme in a research note on Wednesday, June 7th. CIBC reiterated an “outperform” rating on shares of Epizyme in a research note on Thursday, April 13th. Finally, Royal Bank Of Canada set a $20.00 target price on Epizyme and gave the company a “buy” rating in a research note on Monday, June 12th. One analyst has rated the stock with a sell rating, one has given a hold rating and eleven have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $23.75.
In related news, insider Peter Tai-Ching Ho sold 15,000 shares of the stock in a transaction on Monday, July 24th. The stock was sold at an average price of $13.44, for a total value of $201,600.00. Following the sale, the insider now owns 22,228 shares in the company, valued at $298,744.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Robert A. Copeland sold 2,500 shares of the stock in a transaction on Tuesday, June 6th. The stock was sold at an average price of $13.45, for a total value of $33,625.00. Following the completion of the sale, the insider now owns 34,038 shares in the company, valued at approximately $457,811.10. The disclosure for this sale can be found here. In the last quarter, insiders sold 50,524 shares of company stock worth $746,797. 25.20% of the stock is owned by company insiders.
Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).
Receive News & Stock Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related stocks with our FREE daily email newsletter.